Search Results

You are looking at 1 - 10 of 1,286 items for :

  • "incidence" x
  • Refine by Access: All x
Clear All
Full access

Kwang-Yu Chang, Jang-Yang Chang, and Yun Yen

: 1849 – 1853 . 13 Mouzas IA Dimoulios P Vlachonikolis IG . Increasing incidence of cholangiocarcinoma in Crete 1992-2000 . Anticancer Res 2002 ; 22 : 3637 – 3641 . 14 Shaib YH Davila JA McGlynn K El-Serag HB . Rising incidence

Full access

Shiva Kumar R. Mukkamalla, Hussain M. Naseri, Byung M. Kim, Steven C. Katz, and Vincent A. Armenio

and ECC. 2 Incidence and mortality of CCA have been reported to be increasing in the United States. 3 Although reasons for the increased incidence are unclear, it is thought to be partly from improved diagnostic techniques with higher detection rates

Full access

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna

Clostridium difficile infection (CDI) is the most common nosocomial infection in the United States, 1 with increasing recognition in the community. 2 , 3 An increase in incidence and severity of CDI has been observed despite increased awareness

Full access

Mikkael A. Sekeres

Incidence and Prevalence In 2001, the SEER program of the NCI and CDC began to track incidence rates of MDS. Based on the data collected from 2001 to 2003, the age-adjusted incidence rate of MDS in the United States was estimated to be 3.4 per 100

Full access

P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose

selection process. Outcomes The main endpoints of the study were incidence of definitive treatment with prostatectomy or radiation, metastasis, PCSM, and all-cause mortality. We identified definitive treatment using diagnosis and procedural codes and

Full access

Reith R. Sarkar, Katherine E. Fero, Daniel M. Seible, Neil Panjwani, Rayna K. Matsuno, and James D. Murphy

of hospitalization, we used competing risk models to account for the competing risk of death, 9 which included unadjusted cumulative incidence analyses with differences between groups assessed with Gray’s test for inequality. Multivariable Fine

Full access

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson

patients treated and AEs reported were recorded. Observed incidence of AE was reported with 95% CI. Heterogeneity was evaluated using Cochran Q statistic and I2 statistics quantified the proportion of heterogeneity not due to chance. Results: Databases

Full access

Thi My Hanh Luong, Daisuke Niino, Hisayoshi Kondo, Shiro Miura, Masahiro Nakashima, and Masako Iwanaga

Background: Malignant lymphoma (ML) is a heterogeneous neoplasm with a wide range of etiological factors, pathological patterns, incidence rates, and outcomes. Most epidemiological studies have reported the incidence pattern of ML by simply

Full access

Victoria T. Brown, Dana Drzayich Antol, Patrick N. Racsa, Melea A. Ward, and Jarushka Naidoo

Background: Anti-PD1/PD-L1 therapy is standard-of-care for patients with a variety of advanced malignancies. Although clinical trials report a lower incidence of grade 3-4 toxicities than observed with cytotoxic agents, it is imperative that

Full access

Kyaw Z. Thein, Sriman Swarup, Anita Sultan, Subhanudh Thavaraputta, Myo H. Zaw, Nicholas D’Cunha, Sanjay Awasthi, Fred Hardwicke, and Lukman Tijani

,703 patients, comparing cabozantinib (C) vs everolimus, C vs placebo, C vs prednisone, were included. I 2 statistic was 70.70, suggesting some heterogeneity among RCTs. All grade-PPE incidence was 666 (39.3%) in cabozantinib arm vs 38 (3.76%) in control arm